Compare CPAC & ANNX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | CPAC | ANNX |
|---|---|---|
| Founded | 1949 | 2011 |
| Country | Peru | United States |
| Employees | N/A | N/A |
| Industry | Building Materials | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 888.7M | 812.7M |
| IPO Year | 2003 | 2020 |
| Metric | CPAC | ANNX |
|---|---|---|
| Price | $12.70 | $4.90 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | $12.90 | ★ $16.50 |
| AVG Volume (30 Days) | 66.3K | ★ 2.6M |
| Earning Date | 04-24-2026 | 05-11-2026 |
| Dividend Yield | ★ 5.23% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $4.49 | N/A |
| Revenue Next Year | N/A | $16,320.74 |
| P/E Ratio | $19.78 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $5.66 | $1.85 |
| 52 Week High | $12.27 | $7.18 |
| Indicator | CPAC | ANNX |
|---|---|---|
| Relative Strength Index (RSI) | 84.05 | 43.86 |
| Support Level | $10.30 | $4.80 |
| Resistance Level | N/A | $5.07 |
| Average True Range (ATR) | 0.29 | 0.36 |
| MACD | 0.19 | -0.02 |
| Stochastic Oscillator | 100.00 | 30.14 |
Cementos Pacasmayo SAA is a Peruvian cement company, and only cement manufacturer serving in the northern region of Peru. It produce, distribute and sell cement and cement-related materials, such as precast products and ready-mix concrete. Its products are mainly used in construction, which has been one of the fastest growing segments of the Peruvian economy in recent years. It also produce and sell quicklime for use in mining operations. It also provide transportation services. It has three operating segments cement, concrete, mortar, pavement and precast; quicklime; and sales of construction supplies. The majority of profit comes from Cement segment. Peru's cement production is into three regions northern region, central region, including Lima's metropolitan area, and southern region.
Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502, for Oral small molecule; and ANX009, for systemic autoimmune diseases.